Navigation Links
Herding cancer cells to their death
Date:6/20/2013

June 20, 2013, New York, NY and Oxford, UK An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors. This cellular heterogeneity is what makes advanced tumors so difficult to treat. Publishing their findings in today's online issue of Cancer Cell, an international team of scientists led jointly by Professors Colin Goding from the Ludwig Institute for Cancer Research who is based at the University of Oxford and Jos Neptuno Rodriguez-Lpez from the University of Murcia, Spain describe a therapeutic strategy that manipulates a mechanism driving that heterogeneity to treat advanced melanoma. Their preclinical studies show that the strategy, which employs a new drug-like molecule in combination with an existing chemotherapy, is highly specific to melanoma cells and effective against tumors that resist all other therapies.

If caught early, melanoma is relatively easy to treat. But in its late stages, it is a stubborn and deadly cancer. Until about a decade ago, patients survived only about seven months after starting treatment. Since then, therapies, such as vemurafenib, that specifically target signaling proteins essential to the proliferation and survival of melanoma cells have extended the lives of some patients. But only about half respond to these targeted therapies, and even in those patients the cancer begins to resist the targeted therapy within six to nine months.

To bypass such resistance, the researchers developed a strategy that essentially pushes subtypes of melanoma cells that are not dividingand are therefore not susceptible to chemotherapyto become vulnerable to a shrewdly targeted drug.

To develop their therapy, the scientists first screened a variety of molecules to find one that boosts the expression of MITF, a master gene that, at high levels, pushes melanoma cell
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. No danger of cancer through gene therapy virus
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
4. Using math to kill cancer cells
5. Gene variants may predict who will benefit from breast cancer prevention drugs
6. Nanotechnology helps track and improve drug action in pancreatic cancer
7. Biomarker identification may lead to new noninvasive test for colorectal cancer detection
8. First dual-action compound kills cancer cells, stops them from spreading
9. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
10. U of A medical researchers ID genetic marker for sporadic breast cancer
11. Modulating the immune system to combat metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... and rheumatoid arthritis occur when the immune system fails ... where the molecular breakdowns responsible for such failures occur. ... and the Dana-Farber Cancer Institute have identified a key ... autoimmune disease, findings that may help scientists develop new ...
... fillet every now and again could add as much as ... first time that food enriched with natural isotopes builds bodily ... The concept has been demonstrated in worms and researchers hope ... reduce the risk of cancer and other diseases of ageing, ...
... University of Virginia researchers have discovered that microRNAs, a form ... studies. , In the May 1 issue of Genes ... Dutta have shown that microRNAs can suppress the overexpression of ... of fatty tissue and certain tumors, as well as diet-induced ...
Cached Biology News:Cracking open the black box of autoimmune disease 2Meat and two neutrons -- the key to a longer life 2
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 /PRNewswire/ ... and development of therapeutic antibodies, today announced ... (IL-36R) antibody program into IND-enabling studies. The ... a novel treatment for generalized pustular psoriasis ... high unmet medical need. ANB019 is wholly owned ...
(Date:4/16/2015)... , April 16, 2015 ... ™ , a Swiss-based global biopharmaceutical company ... needs as well as companion diagnostics, today ... compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR ... 2015 Annual meeting of the American Association for Cancer Research (AACR) ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... today announced the,appointment of Stephen Smith as Vice ... oversee the US Oncology Research,Network, which provides research ... nationwide US Oncology Network., The research network ... scientific, evidence-based medicine and share best practices. It,has ...
... Exchange Symbol: RVX, CALGARY, Aug. 25 /PRNewswire-FirstCall/ ... pleased to announce that the,Phase 1b/2a program for ... lipids,and those with low high-density lipoprotein (HDL) cholesterol ... excited about moving forward into this important 28-day,study ...
... is pleased to welcome Richard Duffey, M.D., to ... in Mobile, Alabama and also serves patients from ... and Pascagoula communities in Mississippi.,Trusted LASIK Surgeons launched ... and information resource for consumers at www.TrustedLASIKSurgeons.com ...
Cached Biology Technology:US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services 2Phase 1b/2a Program Commences for RVX-208 2Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 2Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 3Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 4Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 5Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 6
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Gentamicin sulfate, 5g...
Biology Products: